Tempus AI Sees Unusually High Options Volume (NASDAQ:TEM)

Tempus AI, Inc. (NASDAQ:TEM) was the target of some unusual options trading activity on Thursday. Stock investors acquired 33,967 call options on the company. This is an increase of approximately 37% compared to the typical volume of 24,823 call options.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on TEM shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tempus AI in a research note on Wednesday, June 17th. Guggenheim dropped their price target on shares of Tempus AI from $95.00 to $60.00 and set a “buy” rating for the company in a research note on Monday, March 30th. Needham & Company LLC restated a “buy” rating and issued a $75.00 price objective on shares of Tempus AI in a report on Monday, June 1st. BTIG Research reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Tempus AI in a research note on Monday, June 1st. Finally, Jefferies Financial Group initiated coverage on shares of Tempus AI in a research report on Monday, April 13th. They set an “underperform” rating and a $35.00 target price for the company. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $68.54.

Tempus AI Stock Up 2.3%

Shares of Tempus AI stock opened at $56.14 on Friday. The firm has a market cap of $10.08 billion, a PE ratio of -32.64 and a beta of 3.62. The business’s 50 day simple moving average is $50.07 and its 200 day simple moving average is $55.08. The company has a debt-to-equity ratio of 2.96, a quick ratio of 3.15 and a current ratio of 3.31. Tempus AI has a 52-week low of $41.73 and a 52-week high of $104.32.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. The firm had revenue of $348.12 million during the quarter, compared to the consensus estimate of $345.44 million. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The business’s revenue was up 36.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.24) EPS. On average, analysts predict that Tempus AI will post -1.35 earnings per share for the current fiscal year.

Insider Transactions at Tempus AI

In other news, EVP Andrew Polovin sold 8,703 shares of the company’s stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total transaction of $383,541.21. Following the transaction, the executive vice president owned 128,215 shares of the company’s stock, valued at $5,650,435.05. This represents a 6.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Ryan M. Bartolucci sold 4,116 shares of the firm’s stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total value of $181,392.12. Following the completion of the transaction, the chief accounting officer owned 74,041 shares in the company, valued at approximately $3,262,986.87. This represents a 5.27% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 392,307 shares of company stock worth $18,901,264 over the last ninety days. 24.26% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of TEM. Vanguard Group Inc. boosted its stake in Tempus AI by 8.7% in the 4th quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock valued at $605,772,000 after purchasing an additional 817,014 shares during the period. ARK Investment Management LLC grew its holdings in Tempus AI by 5.3% in the 4th quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock valued at $446,275,000 after buying an additional 381,816 shares in the last quarter. GC Wealth Management RIA LLC bought a new position in Tempus AI during the 4th quarter worth $399,267,000. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Tempus AI by 23.4% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after buying an additional 821,490 shares in the last quarter. Finally, Amova Asset Management Americas Inc. lifted its holdings in shares of Tempus AI by 23.4% during the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock worth $195,549,000 after buying an additional 821,490 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.